Mga - MAX dimerization protein MGA Gene
Also Known as RGD1561597
Species: Rattus norvegicus
Gene Type: protein coding
Gene ID: 499874
Summary
Predicted to enable DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in cell fate specification and positive regulation of transcription by RNA polymerase II. Predicted to act upstream of or within cellular response to Leukemia Inhibitory Factor. Predicted to be part of MLL1 complex and transcription regulator complex. Orthologous to human MGA (MAX dimerization protein MGA). [provided by Alliance of Genome Resources, Apr 2022]
Mga Products (12)
| mRNA | Protein | Name |
|---|---|---|
| XM_008762120.3 | XP_008760342.1 | MAX gene-associated protein isoform X1 |
| XM_006234799.4 | XP_006234861.1 | MAX gene-associated protein isoform X1 |
| XM_039106509.1 | XP_038962437.1 | MAX gene-associated protein isoform X8 |
| XM_039106508.1 | XP_038962436.1 | MAX gene-associated protein isoform X7 |
| XM_039106504.1 | XP_038962432.1 | MAX gene-associated protein isoform X2 |
| XM_006234798.3 | XP_006234860.1 | MAX gene-associated protein isoform X1 |
| XM_006234797.4 | XP_006234859.1 | MAX gene-associated protein isoform X1 |
| XM_039106503.1 | XP_038962431.1 | MAX gene-associated protein isoform X1 |
| XM_006234800.4 | XP_006234862.1 | MAX gene-associated protein isoform X3 |
| XM_039106505.1 | XP_038962433.1 | MAX gene-associated protein isoform X4 |
| XM_039106506.1 | XP_038962434.1 | MAX gene-associated protein isoform X5 |
| XM_039106507.1 | XP_038962435.1 | MAX gene-associated protein isoform X6 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
MAX gene-associated protein |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive MoleculesInhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99222 | Teplizumab | 99.0% | Unkown |
Clinical Phase
Bioactive MoleculesInhibitory Antibodies
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P9966 | Enoblituzumab | Inhibitor | 99.16% | Phase 3 |
| HY-P99941 | Retifanlimab | 96.84% | Phase 3 | |
| HY-P990027 | Izeltabart | Inhibitor | 98.62% | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(11)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-N3686 | D-Arabitol | Activator | 99.92% | Unkown |
| HY-111614 | Melengestrol acetate | Activator | 99.76% | Unkown |
| HY-N3686S | D-Arabitol-13C | Activator | / | Unkown |
| HY-N3686S1 | D-Arabitol-13C-1 | Activator | / | Unkown |
| HY-N3686S2 | D-Arabitol-13C-2 | Activator | / | Unkown |
| HY-RS08395 | MGA Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS08396 | MGAM Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-179853 | MGA-C13 | / | Unkown | |
| HY-N13366 | 3-Methylcrotonyl CoA | / | Unkown | |
| HY-RS18218 | Mga Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS24695 | Mga Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service